Substrate Report for: Valgancyclovir
Valgancyclovir | Type | Purine |
| | Drug |
| | Not A/B H target |
| Other_Name (5) |
| Chemical_Nomenclature | [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate |
| Formula | C14H22N6O5 |
| CAS_number | 175865-60-8 |
| MW | 354.36 |
| |
| Paper | Sun_2010_Mol.Pharm_7_2362 |
| | Hu_2018_Biochem.Pharmacol_156_147 |
| | Lai_2008_J.Biol.Chem_283_9318 |
| | Kim_2004_Mol.Pharm_1_117 |
| Comment | This is a prodrug of ganciclovir related to valacyclovir |
| Gene_locus | human-BPHL |
| | mouse-bphl |
| CID | 64147 |
| Family | Valacyclovir-hydrolase |
| InChIKey | WPVFJKSGQUFQAP-GKAPJAKFSA-N |
| CanonicalSMILES | CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1NC(=NC2=O)N)N |
| InChI | InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1 |
| IupharLig | 4716 |
| Wikipedia | Valgancyclovir |
|
|